RecruitingPHASE1, PHASE2NCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stephan Grupp MD PhD
Principal Investigator
Regina Myers, MD
Children's Hospital of Philadelphia
Intervention
Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)(biological)
Enrollment
93 enrolled
Eligibility
29 years · All sexes
Timeline
20232029

Study locations (1)

Collaborators

University of Pennsylvania

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05674175 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials